A phase II study of humanized anti-HER2 monoclonal antibody (rhuMAB HER2) and weekly chemotherapy in women with metastatic progressive breast cancer

被引：0
|
作者：
Colozz, M
Gori, S
Mosconi, AM
Di Stefano, A
Mazzoni, F
Maestri, A
Cherubini, R
Crino, L
Tonato, M
机构：
[1] Monteluce Policlin, UO Oncol Med, Perugia, Italy
[2] Osped Bellaria, UO Oncol Med, Bologna, Italy
来源：
ANNALS OF ONCOLOGY | 2000年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
E20
引用
收藏
页码：39 / 39
页数：1
相关论文
共 50 条
  • [1] Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
    Y Tokuda
    T Watanabe
    Y Omuro
    M Ando
    N Katsumata
    A Okumura
    M Ohta
    H Fujii
    Y Sasaki
    T Niwa
    T Tajima
    British Journal of Cancer, 1999, 81 : 1419 - 1425
  • [2] Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
    Tokuda, Y
    Watanabe, T
    Omuro, Y
    Ando, M
    Katsumata, N
    Okumura, A
    Ohta, M
    Fujii, H
    Sasaki, Y
    Niwa, T
    Tajima, T
    BRITISH JOURNAL OF CANCER, 1999, 81 (08) : 1419 - 1425
  • [3] Pathological evaluation of HER2 overexpression: For the treatment of metastatic breast cancers by humanized anti-HER2 monoclonal antibody (trastuzumab)
    Umemura, S
    Sekido, Y
    Itoh, H
    Osamura, RY
    ACTA HISTOCHEMICA ET CYTOCHEMICA, 2002, 35 (02) : 77 - 81
  • [4] Phase II study of weekly intravenous recombinant humanized Anti-p185(HER2) monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast
    Baselga, J
    Tripathy, D
    Mendelsohn, J
    Baughman, S
    Benz, CC
    Dantis, L
    Sklarin, NT
    Seidman, AD
    Hudis, CA
    Moore, J
    Rosen, PP
    Twaddell, T
    Henderson, IC
    Norton, L
    JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) : 737 - 744
  • [5] Trastuzumab, a humanized anti-HER2 monoclonal antibody, for the treatment of breast cancer
    Albanell, J
    Baselga, J
    DRUGS OF TODAY, 1999, 35 (12): : 931 - 946
  • [6] Anti-HER2 monoclonal antibody therapy with adjuvant chemotherapy for breast cancer
    Perez, Edith A.
    ANNALS OF ONCOLOGY, 2006, 17 : 39 - 39
  • [7] Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
    Cobleigh, MA
    Vogel, CL
    Tripathy, D
    Robert, NJ
    Scholl, S
    Fehrenbacher, L
    Wolter, JM
    Paton, V
    Shak, S
    Lieberman, G
    Slamon, DJ
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) : 2639 - 2648
  • [8] A case with HER2-overexpressing breast cancer completely responded to humanized anti-HER2 monoclonal antibody
    Ohta, M
    Tokuda, Y
    Suzuki, Y
    Kubota, M
    Watanabe, T
    Fujii, H
    Sasaki, Y
    Niwa, T
    Makuuchi, H
    Tajima, T
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2001, 31 (11) : 553 - 556
  • [9] The effects of HER2 monoclonal antibody in women with HER2-overexpressing metastatic breast cancer
    Boer R.
    Breast Cancer Research, 1 (1)
  • [10] Evaluation of HER2 status: For the treatment of metastatic breast cancers by humanized anti-HER2 monoclonal antibody (trastuzumab) (Pathological committee for optimal use of trastuzumab)
    Shinobu Umemura
    Goi Sakamoto
    Hironobu Sasano
    Hitoshi Tsuda
    Futoshi Akiyama
    Masafumi Kurosumi
    Yutaka Tokuda
    Toru Watanabe
    Masakazu Toi
    Tadashi Hasegawa
    R. Yoshiyuki Osamura
    Breast Cancer, 2001, 8 (4) : 316 - 320
12345